Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.49 |
| ▸ | HTR2C | P28335 | 10/20 | 0.44 |
| ▸ | QDPR | P09417 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 2/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7669379 | 0.88 | HTR3A (0.52) | SLC18A3SIGMAR1GABRA1GABRG2GABRB3 | |
| SCHEMBL7669376 | 0.88 | HTR3A (0.52) | SLC18A3SIGMAR1GABRA1GABRG2GABRB3 | |
| SCHEMBL18825946 | 0.80 | KDR (0.41) | GABRA1GABRG2GABRB3HCAR2 | |
| SCHEMBL3089324 | 0.80 | — | — | |
| SCHEMBL31087550 | 0.78 | KDR (0.43) | SLC18A3HCAR2 | |
| SCHEMBL146605 | 0.78 | KDR (0.43) | SLC18A3HCAR2 | |
| SCHEMBL10726486 | 0.77 | HCAR2 (0.36) | GABRA1GABRG2GABRB3HCAR2 | |
| SCHEMBL24067500 | 0.77 | SLC18A3 (0.64) | SLC18A3SIGMAR1GABRA1GABRG2GABRB3 | |
| SCHEMBL12526246 | 0.75 | HCAR2 (0.35) | HCAR2 | |
| SCHEMBL1365978 | 0.75 | HCAR2 (0.38) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-7491737-B2 | Heterarylpiperidine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491737-B2 | Heterarylpiperidine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7247725-B2 | Gamma-aminoamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247725-B2 | Gamma-aminoamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-0272208-B1 | AROMATICALLY SUBSTITUTED AZACYCLO-ALKYLALKANEDIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1991-06-12 | — | — | EP | disclosed |
| US-4871720-A | Aromatically substituted azacycloalkyl-alkanediphosphonic acids useful for the treatment of illnesses that can be attributed to calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0272208-A1 | Aromatically substituted azacyclo-alkylalkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | SLC18A3 222/4885SIGMAR1 1873/4885GABRA1 3338/4885 |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | CX3CR1, CCL2, CCR5 | SLC18A3 222/4885SIGMAR1 1873/4885GABRA1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.